Stablepharma appoint two new members to the team in the UK and the R&D site in Madrid.

We are thrilled to announce two new additions to the Stablepharma team. Please welcome Michelle Hennessy, Financial Manager and Veronica Daza, Formulation Manager to UK and Spain offices.

Copy for Press Release

Stablepharma is delighted to welcome two new members to the UK and Spain teams. Verónica Daza, Formulation Manager is working together with Dr Arcadio García de Castro and Juana de la Torre, based at Qube Technology Park, Madrid (Spain) and Michelle Hennessy has joined the UK team as Finance Manager, working closely with Neil Mayall, CFO.

We are delighted that Veronica and Michelle are part of the expanding Stablpharma team, both are highly qualified in their specific areas of science and finance and offer a real value-add to the business as we continue to grow and develop our technology in the area of ‘fridge-free’ vaccines”, said Ozgur Tuncer, CEO & Executive Director of Stablepharma.

With a degree in Pharmacy and a Master´s degree in Pharmaceutical Industry, Project Management and advanced training in Good Manufacturing Practices (GMP). “Veronica started her scientific career as a researcher in the Pharmaceutical Development Department at the University of Seville and since then, has worked in various pharmaceutical companies, such as Insud Pharma and Damel group and as such, is a great addition to our team here at the Qube in Madrid”, said Dr Arcadio García de Castro.

I am delighted to be part of the team at Stablepharma. It is a company that is truly focused on innovation and has the technology to make a real difference in the world. I want to be part of the solution that will increase access of vaccines globally and to participate, personally, in improving the society´s quality of life”. In addition to Veronica’s qualifications, she has a personal interest in writing articles for global scientific journals about Galenical development.

Michelle Hennessy has joined the Finance team, with over 15 years of experience as an accountant, having worked with KPMG and GAVI. She is a fellow of Chartered Accountants Ireland and brings with her a wealth of experience in management of day to day finance operations.

Neil Mayall, CFO of Stablepharma added, “Michelle is the perfect candidate for our team in London, as well as bringing a European perspective of business and strong Spanish language skills, which will be of enormous value to the Science team in Madrid. We are delighted she has joined the team”. “This is a really interesting venture for me within the biotech industry’, said Michelle, ‘working with a business that has a novel technology and a strong Management team. Stablepharma is a true pioneer for emerging vaccine technology and their mission of developing an innovative global healthcare solution is very inspiring”. 


Available for comment, contribution and collaboration are:

About Stablepharma

Stablepharma is an innovative biotech company developing a wide range of next generation, reformulated thermostable vaccine products. Currently, Stablepharma is working with partners on two major stabilisation programmes: the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio), developing a thermally stable version of the Tetanus diphtheria (Td) vaccine using the patent StablevaX™ formulation and device, moving onto FIH (First in Human) clinical trials with StablevaX Td (Tetanus diphtheria). And Stablepharma’s COVID mRNA programme in partnership with the University of Strathclyde.

StablevaX™ is a novel thermo-stabilisation technology and reformulation platform with strong in-vitro and in-vivo animal potency data that aims to eliminate the cold chain.